Riskpilot← Back to searchSign inGet full accessISR Oncology AB
ABBankruptOrg 5591573760Research and experimental development on natural sciences and engineering · NACE 7210Est. 20180 employees
Revenue 2022
SEK 0
EBITDA margin
—
-1500% vs 2021
Equity ratio
-31.6%
Financial strength
Net profit 2022
SEK -64K
-1500% vs 2021
| Revenue | SEK 0 | — |
| EBITDA | SEK -64K | -1500% |
| Net profit | SEK -64K | -1500% |
| Total assets | SEK 19K | -72% |
| Equity | SEK -6K | -111% |
| Employees | 0 | — |
Legal name
ISR Oncology AB
Org number
5591573760
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
27 april 2018
Share capital
SEK 50 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2022-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas två i förening av ledamöterna Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Bolaget ska bedriva forskning inom onkologi samt därmed förenlig verksamhet.
Address
Email
johan@jpnylund.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Staff expenses | — | — | — | — | — |
| EBITDA | −8 | −9 | 2 | −4 | −64 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 |
| EBIT | −8 | −9 | 2 | −4 | −64 |
| Net financials | — | — | — | — | — |
| Profit before tax | −8 | −9 | 2 | −4 | −64 |
| Tax | −0 | −0 | −0 | −0 | −0 |
| Net profit | −8 | −9 | 2 | −4 | −64 |
| Item | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| Total assets | 50 | 49 | 46 | 67 | 19 |
| Equity | 43 | 34 | 36 | 57 | −6 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 8 | 15 | 10 | 10 | 26 |
| Total debt | 8 | 15 | 10 | 10 | 26 |
EBITDA margin
-6400000.0%
This company
15.8%
Market median
-40506429% vs market
20182022
Equity ratio
-31.6%
This company
38.2%
Market median
-183% vs market
20182022
Return on equity
-6400000.0%
This company
18.4%
Market median
-34782709% vs market
20182022
Net profit margin
-6400000.0%
This company
8.1%
Market median
-79012446% vs market
20182022
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20182022
Debt / equity
4.17×
This company
0.62×
Market median
-573% vs market
20182022
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Bolagsverket / SCB · Period 2018-04-01 – 2018-12-31
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Audit | 2024 | |
SO Chief Executive Officer | Chief Executive Officer | 2020 |
| Former (3) | ||
BM Chief Auditor | Chief Auditor | 2020 – 2024 |
SL External Signatory | External Signatory | 2020 – 2021 |
KÅ External Signatory | External Signatory | 2021 – 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (4) | ||
| Board of Directors | 2024 | |
| Board of Directors | 2024 | |
| Board of Directors | 2024 | |
| Chairman | 2024 | |
| Former (4) | ||
| Board of Directors | 2020 – 2023 | |
| Deputy Board Member | 2023 – 2024 | |
| Board of Directors | 2020 – 2024 | |
| Chairman | 2020 – 2024 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 0001 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
ISR Immune System Regulation Holding AB (publ)
ISR Oncology AB Board members of ISR Oncology AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Bo Magnus Lagerberg | Chief Auditor | 0 companies |
| Sven Lennart Dreyer | External Signatory | 0 companies |
| Ben Behnam Mahajerzadeh-Heidari | Audit | 0 companies |
| Karl Åke Gunnar Modalen | External Signatory | 0 companies |
| Stig Ola Winqvist | Chief Executive Officer | 0 companies |
| Carl Henrik Egertun | Board of Directors | 0 companies |
| Hans Olof Glise | Board of Directors | 0 companies |
| Stig Jonas Winqvist | Deputy Board Member | 0 companies |
| Aleksandar Gocic | Board of Directors | 0 companies |
| Johan Peter Nylund | Board of Directors | 0 companies |
| Jan Krister Magnelöv | Chairman | 0 companies |
| Jan Erik Gunnar Jardelöv | Board of Directors | 0 companies |
| Anders Harald Milton | Chairman | 0 companies |